Lee, Chun Kyon

Publishing since 1967 (Dinosaur)

Has published 356 publications in 44 years

Number of publications published per year by Lee, Chun Kyon. (Source : PubMed)

Distribution of publications types for Lee, Chun Kyon. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW. Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity.  Vaccine  2010  
•  Reesink HW, Panzer S, Gonzalez CA, Lena N, Muntaabski P, Gimbatti S, Wood E, Lambermont M, Deneys V, Sondag D, Alport T, Towns D, Devine D, Turek P, Auvinen MK, Koski T, Lin CK, Lee CK, Tsoi WC, Lawlor E, Grazzini G, Piccinini V, Catalano L, Pupella S, Kato H, Takamoto S, Okazaki H, Hamaguchi I, Wiersum-Osselton JC, van Tilborgh AJ, Zijlker-Jansen PY, Mangundap KM, Schipperus MR, Dinesh D, Flanagan P, Flesland O, Steinsvåg CT, Espinosa A, Letowska M, Rosiek A, Antoniewicz-Papis J, Lachert E, Koh MB, Alcantara R, Corral Alonso M, Muñiz-Diaz E. Haemovigilance for the optimal use of blood products in the hospital.  Vox Sang.  2010  
•  Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J, Sirisanthana T, Chen YM, Pujari S, Kumarasamy N, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang FJ, Mean CV, Merati T, Tau G, Smith J, Li PC. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).  HIV Med.  2010  
•  Kim YG, Lee CK, Kim SH, Cho WS, Mun SH, Yoo B. Interleukin-32gamma enhances the production of IL-6 and IL-8 in fibroblast-like synoviocytes via Erk1/2 activation.  J. Clin. Immunol.  2010;30;2  
•  Lee CK, Cheong C, Jeon YH. The N-terminal domain of human holocarboxylase synthetase facilitates biotinylation via direct interaction with the substrate protein.  FEBS Lett.  2010;584;4  
•  Wu JT, Lee CK, Cowling BJ, Yuen KY. Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic.  Proc. Natl. Acad. Sci. U.S.A.  2010;107;7  
•  Leung VK, Lee CK, Chau TN, Cheung WI, Lo FH, Lai KB, Lin CK. A probable case of transfusion-transmitted hepatitis B virus infection in an immunosuppressed recipient caused by an occult HBV-infected donor with negative ID-NAT.  Transfus Med  2010  
•  Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim do Y, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.  Hepatology  2010;51;2  
•  Lee CK, Lord SJ, Stockler MR, Coates AS, Gebski V, Simes RJ. Historical cross-trial comparisons for competing treatments in advanced breast cancer--an empirical analysis of bias.  Eur. J. Cancer  2010;46;3  
•  Oh JS, Kim YG, Lee SG, Lee CK, Yoo B. Successful treatment of recurrent lupus enteritis with rituximab.  Lupus  2010;19;2  

[ See timeline ] [ See all publications ]